No increase in subtrochanteric or diaphyseal femur fractures was seen with denosumab use compared with bisphosphonates in 4 ...

A major UK-based study has found that denosumab, a widely used osteoporosis medication, does not raise the risk of atypical femur fractures compared with bisphosphonates over four years. The result ...

Adults with osteoporosis prescribed the antiresorptive denosumab were no more likely to sustain an atypical femur fracture ...

THOUSAND OAKS, Calif., May 8, 2023 /PRNewswire/ -- Amgen (AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare ...

A large real-world study of nearly 300,000 osteoporosis patients found no increased risk of atypical femur fractures with denosumab compared to bisphosphonates. The findings, presented at the 2026 ...

Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™ (Denosumab biosimilars to Prolia® and Xgeva®) for bone health.

Denosumab therapies are used to increase bone mass and treat osteoporosis, as well as address bone complications in cancer.

Longer durations of denosumab treatment improved the probability of achieving target T-scores at the total hip and lumbar spine in postmenopausal women with osteoporosis. Denosumab treatment ...

Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...

Xgeva and Prolia are two drugs Amgen investors need to keep an eye on. Thanks to label expansion that permitted wider use of the drugs, they've been Amgen's fastest-growing products this past year.